is it normal to get food noise at week 47
is it normal to get food noise at week 47, and the part I actually want to talk about is at the bottom.
Read the combination paper twice before saying anything here. The monotherapy and combination arms tell genuinely different stories.
The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.
Yes. Anyone reading this board should hold their conclusions loosely until phase 3 reports.
What does the tolerability table in that paper actually say?
amylin and GLP-1 are not redundant pathways
Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.
How many separate lots has anyone here tested?
Which receptor family are you attributing that effect to?
Careful — that is a dosing intuition carried over from another board and there is no basis for it here.
Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.
the interesting data is the combination, not the monotherapy
Push back: the evidence base here is thin enough that a confident ranking against the established compounds is not supportable.
this is a less-travelled board and the evidence base shows it
Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.
That result is preclinical. Worth flagging, since the thread has been reading it as human data.
Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.
Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.
Small fix — amylin analogue, not a GLP-1 analogue.
Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.
Which trial and which readout?
do not assume the dosing intuitions from the GLP-1 boards transfer
Which trial and which readout?
This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.
- 1Nothing containing this compound is approved as a standalone product, and…8 comments in this branch · started by u/incretin_ivy
- 2Dosing intuitions from the GLP-1 boards do not transfer. Different receptor…6 comments in this branch · started by u/teodor_lokken